Navigation Links
MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results

Keflex Product Sales Grow to $10.5 Million in 2007; MOXATAG, Company's Lead PULSYS Product, Approved Following Year-end; Process to Explore Strategic

Alternatives Ongoing

GERMANTOWN, Md., March 4 /PRNewswire-FirstCall/ -- MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK), a pharmaceutical company focused on developing and commercializing novel anti-infective products, today announced financial and operational results for the quarter and fiscal year ended December 31, 2007.

MiddleBrook reported fourth quarter 2007 revenue of $2.9 million, compared to revenue of $3.1 million in the third quarter of 2007 and $1.2 million in the fourth quarter of 2006. Revenue for the full year of 2007 increased to $10.5 million, up 117% from revenue of $4.8 million for the full year of 2006.

MiddleBrook reported research and development (R&D) expenses in the fourth quarter of $3.5 million, down from third quarter 2007 R&D expenses of $5.5 million and fourth quarter 2006 R&D expenses of $6.3 million. For the full year of 2007, R&D expenses declined to $22.0 million, from $26.0 million in R&D expenses for the full year of 2006.

Total operating expenses for the fourth quarter of 2007 were $9.8 million, down from $13.2 million in the third quarter of 2007 and $14.9 million in the fourth quarter of 2006. However, total expenses for the full year of 2007 increased slightly to $50.6 million, compared to total expenses of $48.2 million in 2006.

Net loss was $9.1 million for the fourth quarter, compared to a net loss of $10.1 million in the third quarter of 2007 and a net loss of $13.8 million in the fourth quarter of 2006. Net loss for the full year of 2007 was $42.2 million, compared to a net loss of $42.o, statements about the Company's product development and commercialization schedule, including, particularly, future plans with respect to its Amoxicillin PULSYS products; any statements regarding Dr. Rudnic's comments and expectations concerning the Company; the Company's initiatives to develop improved antibiotics; the Company's existing and anticipated collaborative agreements; and any financial forecasts and projections for 2008 and thereafter included under the Financial Guidance section of this announcement.

The actual results realized by MiddleBrook could differ materially from these forward-looking statements, depending in particular upon the risks and uncertainties described in the Company's filings with the Securities and Exchange Commission. These include, without limitation, risks and uncertainties relating to the Company's financial results and the ability of the Company to (1) raise additional capital and continue as a going concern, (2) maintain its Keflex 750 sales, (3) retain marketing approval for its MOXATAG product, (4) successfully reduce costs, (5) reach profitability, (6) prove that the preliminary findings for its product candidates are valid, (7) receive required regulatory approvals, (8) successfully conduct clinical trials in a timely manner, (9) establish its competitive position for its products, (10) develop and commercialize products that are superior to existing or newly developed competitor products, (11) develop products without any defects, (12) have sufficient capital resources to fund its operations, (13) protect its intellectual property rights and patents, (14) implement its sales and marketing strategy, (15) successfully attract and retain collaborative partners, (16) successfully commercialize and gain market acceptance for its Keflex products, (17) successfully obtain sufficient manufactured quantities of its drug products at acceptable rates, and (18) retain its senior management and other personnel. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. MiddleBrook undertakes no obligation to update or revise the information in this announcement, whether as a result of new information, future events or circumstances or otherwise.




Three Months Ended Twelve Months Ended

December 31, December 31,

2007 2006 2007 2006

Product sales $2,858,573 $1,243,847 $10,456,700 $4,810,410

Costs and expenses:

Cost of product

sales 712,311 381,836 2,576,954 899,601

Research and

development 3,472,544 6,273,581 21,957,708 25,973,844

Selling, general


administrative 5,569,764 8,287,656 26,043,711 21,288,968

Total expenses 9,754,619 14,943,073 50,578,373 48,162,413

Loss from

operations (6,896,046) (13,699,226) (40,121,673) (43,352,003)

Interest income 61,587 147,764 543,442 895,685

Interest expense (55,352) (218,633) (584,276) (510,651)

Early extinguishment

of debt (224,048) - (224,048) -

Warrant expense (2,100,000) - (2,100,000) -

Other income - - 75,000 976,815

Loss including


interest (9,213,859) (13,770,095) (42,411,555) (41,990,154)

Loss attributable

to noncontrolling

interest 162,189 - 162,189 -

Net loss $(9,051,670) $(13,770,095) $(42,249,366) $(41,990,154)

Basic and diluted

net loss per share $(0.19) $(0.44) $(0.96) $(1.38)

Shares used in

calculation of

basic and diluted

net loss per share 46,734,506 31,503,384 43,816,145 30,535,965




December 31,

2007 2006


Current assets:

Cash and cash equivalents $1,951,715 $14,856,738

Marketable securities - 522,723

Accounts receivable, net 687,787 303,514

Inventories, net 687,933 2,077,390

Prepaid expenses and other

current assets 1,142,905 1,682,685

Total current assets 4,470,340 19,443,050

Property and equipment, net 10,928,659 11,764,627

Restricted cash 872,180 872,180

Deposits and other assets 174,965 1,548,585

Intangible assets, net 7,219,651 8,377,327

Total assets $23,665,795 $42,005,769


Current liabilities:

Accounts payable $1,659,752 $2,285,736

Accrued expenses and advances 5,613,544 7,817,224

Lines of credit and short term debt - 6,888,889

Note payable - 75,000

Deferred product revenue - 189,000

Total current liabilities 7,273,296 17,255,849

Warrant liability 2,100,000 -

Deferred contract revenue 11,625,000 11,625,000

Deferred rent and credit on lease

concession 1,177,840 1,252,900

Total liabilities 22,176,136 30,133,749

Noncontrolling interest 7,337,811 -

Commitments and contingencies

Stockholders' equity (deficit):

Preferred stock, undesignated - -

Common stock, par value 467,488 363,625

Capital in excess of par value 189,019,188 164,593,930

Accumulated deficit (195,334,828) (153,085,462)

Accumulated other comprehensive loss - (73)

Total stockholders' equity (deficit) (5,848,152) 11,872,020

Total liabilities and

stockholders' equity (deficit) $23,665,795 $42,005,769




Year Ended December 31,

2007 2006

Cash flows from operating activities:

Net loss $(42,249,366) $(41,990,154)

Adjustments to reconcile net income

to net cash used in operating


Loss attributable to non-

controlling interest (162,189) -

Depreciation and amortization 4,460,069 3,919,267

Warrant expense 2,100,000 -

Stock-based compensation 1,931,439 3,404,063

Deferred rent and credit on lease

concession (75,060) (15,957)

Amortization of premium on

marketable securities (39,687) 204,525

(Gain) or loss on disposal of fixed

assets - 23,185

Advance payment for sale of Keflex - (1,000,000)

Changes in:

Accounts receivable (384,273) 574,751

Inventories 1,389,457 (1,857,939)

Prepaid expenses and other current

assets 539,780 (885,432)

Deposits other than on property

and equipment 304,151 (30,096)

Accounts payable (625,984) 599,249

Accrued expenses and advances (2,260,048) 534,236

Deferred product and contract revenue (189,000) 189,000

Net cash used in operating

activities (35,260,711) (36,331,302)

Cash flows from investing activities:

Purchase of marketable securities (5,867,519) (13,764,736)

Sale and maturities of marketable

securities 6,430,000 24,355,000

Purchases of property and equipment (1,396,954) (300,929)

Deposits on property and equipment - (250,000)

Proceeds from sale of fixed assets - 25,000

Change in restricted cash - 728,744

Net cash (used in) provided by

investing activities (834,473) 10,793,079

Cash flows from financing activities:

Proceeds from private placement of

common stock and warrants,

net of issuance costs 22,412,260 16,735,804

Proceeds from purchase of

noncontrolling interest 7,500,000 -

Proceeds from issuance of debt, net

of issue costs - 7,792,976

Payments on lines of credit (6,888,889) (2,603,524)

Proceeds from exercise of common

stock options 166,790 352,737

Net cash provided by financing

activities 23,190,161 22,277,993

Net decrease in cash and cash equivalents (12,905,023) (3,260,230)

Cash and cash equivalents, beginning

of period 14,856,738 18,116,968

Cash and cash equivalents, end of period $1,951,715 $14,856,738

0 million in the prior year.

Net loss per share applicable to common stockholders during the fourth quarter of 2007 was ($0.19), compared to a net loss per share of ($0.22) in the prior quarter, and a net loss per share of ($0.44) in the comparable quarter of last year. Net loss per share applicable to common stockholders during the full year of 2007 was ($0.96), down from a net loss per share of ($1.38) in the full year of 2006.

"Having received FDA approval for MOXATAG and raising more than $20 million in the first quarter of 2008, we believe we are now in a very favorable position to be considering strategic alternatives for the Company," stated Edward M. Rudnic, Ph.D., president and CEO of MiddleBrook. "We intend to work closely with Morgan Stanley over the coming months to drive the strategic process toward a potential transaction having the greatest benefit for our shareholders."


Keflex(R) Capsules (Cephalexin, USP) - Commercialization Update

During the fourth quarter, MiddleBrook continued the commercialization of its 750 mg strength Keflex capsules through a targeted and dedicated national contract sales force. Based on prescription data from IMS Health, total prescriptions filled for Keflex 750 mg capsules in the fourth quarter of 2007 were 79,628 prescriptions, compared to third quarter 2007 prescriptions of 83,767.

MiddleBrook is currently marketing Keflex 750 mg capsules through its sales force of approximately 30 contract sales representatives and three MiddleBrook district sales managers.

MOXATAG(TM) (amoxicillin extended-release) Tablets Approval - January 23, 2008

On January 23, 2008, MiddleBrook received U.S. Food and Drug Administration (FDA) approval of the Company's New Drug Application (NDA) for its once-daily amoxicillin PULSYS(R) product, under the trade name, MOXATAG(TM) (amoxicillin extended-release) Tablets. MOXATAG is approved for the treatment of pharyngitis and/or tonsillitis secondary to Streptococcus pyogenes (strep throat) in adults and pediatric patients 12 years or older.

MOXATAG is the first and only once-daily aminopenicillin therapy approved by the FDA to treat strep throat. Physicians prescribing MOXATAG would be able to provide their patients the convenience of once-daily dosing while utilizing approximately one-half the amount of amoxicillin currently used. According to prescription data from IMS Health, more than 30 million prescriptions were written for strep throat, pharyngitis and tonsillitis in the U.S. in 2007.

Keflex Transaction Raises $7.5 Million in Gross Proceeds

As previously announced, MiddleBrook closed an agreement on November 7, 2007, with Deerfield Management, a healthcare investment fund and one of the Company's largest equity shareholders, raising $7.5 million in cash through the sale of the Company's non-PULSYS Keflex assets, which the Company has the option to repurchase in the future.

Under the terms of the agreement, the Company received $7.5 million of gross proceeds, less a $0.5 million payment to Deerfield. The Company has the right to repurchase the assets sold in the transaction for a total of $11.0 million prior to year-end 2009. Proceeds from the agreement allowed MiddleBrook to repay in full its outstanding loan facility with Merrill Lynch and eliminate the associated interest and principal payments.

Equity Financing in January 2008 Raises $21 Million in Gross Proceeds

Subsequent to year-end, MiddleBrook closed a private placement of common stock and warrants to institutional investors, resulting in the receipt of $21.0 million in gross proceeds, less approximately $1.1 million in transaction expenses. The transaction included the private placement of 8,750,000 shares of MiddleBrook common stock and five-year warrants to purchase an additional 3,500,000 shares of common stock.

The Company intends to use the proceeds from the financing to support the manufacture of MOXATAG, and for working capital and general corporate purposes. In addition, the financing is designed to provide the Company with additional financial flexibility in its ongoing strategic discussions.

Process to Explore Strategic Alternatives Ongoing

In February 2008, MiddleBrook announced that it engaged Morgan Stanley as its strategic advisor in the Company's ongoing strategic evaluation process. MiddleBrook is evaluating a full range of available strategic alternatives intended to further enhance shareholder value.

Strategic alternatives the Company may pursue could include, but are not limited to, continued execution of the Company's operating plan, the sale of some or all of the Company's assets, partnering or other collaboration agreements, or a merger or other strategic transaction. There can be no assurance that the exploration of strategic alternatives will result in any agreements or transactions, or that, if completed, any agreements or transactions will be successful or on attractive terms. The Company does not intend to disclose developments with respect to this process unless and until the evaluation of strategic alternatives has been completed.


-- Total revenue, resulting entirely from net Keflex product sales, was

$2.9 million in the fourth quarter of 2007, compared to revenue of $3.1

million in the prior quarter, and $1.2 million for the fourth quarter

of 2006. Revenue during the full year of 2007 was $10.5 million, up

from revenue of $4.8 million during the full year of 2006. Increased

product sales in 2007 were mainly attributable to the Company's Keflex

750 mg strength capsules which were launched during the second half of


-- Operating expenses. Research and development expenses, which primarily

consist of salaries, stock-based compensation, and related expenses for

personnel and the costs the Company's clinical trials and research

initiatives, were $3.5 million in the fourth quarter of 2007, down from

$5.5 million in the previous quarter and $6.3 million in the fourth

quarter of 2006. R&D expenses declined for the full year of 2007 to

$22.0 million, compared to $26.0 million in the prior year. Reduced R&D

expenses resulted mainly from lower spending on the Company's MOXATAG

clinical trial which concluded in 2006.

Selling, general and administrative (SG&A) expenses totaled $5.6

million in the fourth quarter of 2007, down from $6.5 million in the

third quarter of 2007, and $8.3 million in the fourth quarter of 2006.

Fourth quarter SG&A costs declined due to lower third-party costs

associated with the reduced size of Company's contract sales force. For

the full year of 2007, SG&A expenses increased to $26.0 million, from

$21.3 million, as the Company incurred a full year of Keflex 750

selling and marketing expenses in 2007, versus incurring such costs

only during a portion of 2006.

-- Other expenses for the fourth quarter of 2007 included a $2.1 million

noncash expense for the contractual value of warrants issued to

Deerfield Management pursuant to the Keflex transaction in the quarter.

There were no such expenses in prior periods.

-- Net loss for the fourth quarter of 2007 was $9.1 million. This compares

to a net loss of $10.1 million in the third quarter of 2007, and $13.8

million in the fourth quarter of 2006. Net loss for the full year of

2007 was $42.2 million, compared to a net loss of $42.0 million for the

full year of 2006. The net loss for the three months and full year

ended December 31, 2007, was reduced by $0.2 million attributable to

the loss from noncontrolling interest in two companies affiliated with

Deerfield Management pursuant to the Keflex transaction, resulting from

MiddleBrook's consolidation of the two affiliates under Financial

Accounting Standards Board Interpretation No. 46 (revised 2003)

"Consolidation of Variable Interest Entities."

-- Net loss per share applicable to common stockholders for the fourth

quarter of 2007 was ($0.19), compared to a loss per common share of

($0.22) in the prior quarter and ($0.44) in the fourth quarter of 2006.

For the fiscal year of 2007, net loss per share applicable to common

stockholders was ($0.96), down from ($1.38) for the fiscal year of


Per share figures were computed on the basis of an average of 46.7

million shares outstanding in the fourth quarter of 2007, 46.7 million

shares outstanding in the third quarter of 2007, 31.5 million shares

outstanding in the fourth quarter of 2006; and 43.8 million shares

outstanding for the full year of 2007 and 30.5 million shares

outstanding for the full year of 2006.

-- Cash and marketable securities decreased by $4.0 million during the

fourth quarter. Changes were composed of $6.9 million of operating

losses, $4.9 million in loan payments, and $2.3 million for working

capital changes and other items; offset by $7.0 million raised from the

Deerfield Management Keflex transaction and $3.1 million for non-cash


-- The Balance Sheet at the end of 2007 reflected $2.0 million of

unrestricted cash, cash equivalents and marketable securities, compared

to $15.4 million as of year-end 2006. Following the fourth quarter of

2007, MiddleBrook completed a private placement of common stock and

warrants resulting in the addition of $19.9 million of net proceeds to

the Company.


Total revenue for 2008 is expected to be approximately $10 million to $12 million, resulting from Keflex product sales and assuming no generic competition to Keflex 750 mg capsules occurs during the year. Total cash used in operating activities and capital expenditures in 2008 is estimated to be between $17 and $19 million. These forecasts also assume no financial impact from the Company's recently approved MOXATAG product, pending the outcome of its ongoing strategic process.

Assuming the Company's expectations for continued sales of its Keflex 750 mg product and anticipated level of R&D spending and other obligations, MiddleBrook believes that its current funds, together with expected Keflex product sales, will be sufficient to support its currently planned operations into 2009. These 2008 estimates are forward-looking statements that involve risks and uncertainties, and actual results could vary materially.


The Company has scheduled a conference call for today, Tuesday, March 4, 2008 at 10:30 AM ET. During the call, Dr. Edward Rudnic, president and CEO, and Robert Low, vice president, finance and CFO, will discuss quarterly results and other corporate activities. Investors can call 1-800-813-8504 (domestic) and 1-706-643-7752 (international) prior to the 10:30 AM start time and ask for the MiddleBrook Pharmaceuticals conference call hosted by Dr. Rudnic. A replay of the call will be available on Tuesday, March 4, 2008 beginning at 12:30 PM ET and will be accessible until Tuesday, March 11, 2008 at 5:00 PM ET. The replay call-in number is 1-800-642-1687 for domestic callers and 1-706-645-9291 for international callers. The access number is 37507035.

The conference call will also be broadcast simultaneously on the Company's website, Investors should click on the Investor Relations tab and are advised to go to the website at least 15 minutes early to register, download, and install any necessary audio software. The call will also be archived on the MiddleBrook website.

About MiddleBrook Pharmaceuticals:

MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) is a pharmaceutical company focused on the development and commercialization of anti-infective drug products that fulfill substantial unmet medical needs in the treatment of infectious disease. The Company is developing anti-infective drugs based on its novel biological finding that bacteria exposed to antibiotics in front- loaded staccato bursts, or "pulses," are killed more efficiently and effectively than those under standard treatment regimens. Based on this finding, MiddleBrook has developed a proprietary, once-a-day pulsatile delivery technology called PULSYS(R). The Company currently markets the Keflex(R) brand of cephalexin and has received regulatory approval for MOXATAG(TM) - the first and only once-daily amoxicillin product approved for marketing in the U.S. For more on MiddleBrook, please visit


MOXATAG(TM) (amoxicillin extended-release) tablets are a once-a-day extended-release formulation of amoxicillin for oral administration consisting of three components: one immediate-release and two delayed-release. The three components are combined in a specific ratio to prolong the release of amoxicillin from MOXATAG compared to immediate-release amoxicillin. MOXATAG is intended to provide a lower treatment dose, once-daily alternative to currently approved penicillin and amoxicillin regimens for the treatment of adults and pediatric patients 12 years and older with tonsillitis and/or pharyngitis.

About Keflex:

Keflex(R) (cephalexin capsules, USP) is a first-generation cephalosporin antibiotic shown to be active against strains of both gram-positive and gram- negative aerobes in vitro and in clinical infections. Keflex is indicated for treatment of the following infections: respiratory tract infections, otitis media, skin and skin structure infections, bone infections, and genitourinary tract infections. More information on Keflex and prescribing information are available at

This announcement contains historical financial information as of and for three-month and twelve-month periods ended December 31, 2007 and December 31, 2006 that is unaudited, and MiddleBrook assumes no obligation to update this information based on new information or future performance except as may be specifically required by applicable law or regulation. The unaudited annual financial information is subject to audit by independent accountants on an annual basis following the close of each calendar year.

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on MiddleBrook's current expectations and assumptions. These statements are not guarantees of future performance and are subject to a number of risks and uncertainties that would cause actual results to differ materially from those anticipated. The words, "believe," "expect," "intend," "anticipate," and variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward- looking. Statements in this announcement that are forward-looking include, but are not limited t

SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million
2. MiddleBrook Pharmaceuticals to Present at BIO CEO & Investor Conference 2008
3. MiddleBrook Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 4, 2008
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
(Date:10/10/2017)... California (PRWEB) , ... October 10, 2017 , ... Dr. ... speaking at his local San Diego Rotary Club. The event entitled ... Diego, CA and had 300+ attendees. Dr. Harman, DVM, MPVM was joined by ...
(Date:10/10/2017)... ... October 10, 2017 , ... The Pittcon Program ... honoring scientists who have made outstanding contributions to analytical chemistry and ... 2018, the world’s leading conference and exposition for laboratory science, which will be ...
(Date:10/9/2017)... ... October 09, 2017 , ... ... line of medical marijuana products targeting the needs of consumers who are incorporating ... Kindred takes place in Phoenix, Arizona. , As operators of two successful Valley ...
(Date:10/7/2017)... WALTHAM, Mass. , Oct. 6, 2017 /PRNewswire/ ... pioneering work of three scientists, Jacques Dubochet, ... whose breakthrough developments in cryo-electron microscopy ... this technology within the structural biology community. The ... Scientific. Scientists can now routinely produce highly resolved, ...
Breaking Biology Technology:
(Date:7/20/2017)... July 20, 2017 Delta (NYSE: DAL ) customers ... Delta aircraft at Reagan Washington National Airport (DCA). ... Delta launches biometrics to board aircraft ... Delta,s biometric boarding pass ... is now integrated into the boarding process to allow eligible Delta ...
(Date:6/14/2017)... IBM ) is introducing several innovative partner startups at VivaTech ... startups and global businesses, taking place in Paris ... will showcase the solutions they have built with IBM Watson ... France is one of the most dynamic ... in the number of startups created between 2012 and 2015*, ...
(Date:5/16/2017)... 2017   Bridge Patient Portal , an ... MD EMR Systems , an electronic medical record ... have established a partnership to build an interface ... GE Centricity™ products, including Centricity Practice Solution (CPS), ... These new integrations will allow healthcare delivery networks ...
Breaking Biology News(10 mins):